米国の造影剤市場規模、シェア、動向分析レポート：モダリティ別、タイプ別、用途別、セグメント別予測、2023～2030年

米国の造影剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の造影剤市場規模は2023年から2030年にかけてCAGR 4.1％を記録し、2030年には33億6,000万米ドルに達すると予測されています。

慢性疾患の負担増が画像診断の需要を生み出しており、これが市場成長の原動力となっています。MRIなどの画像検査は、ほとんどの疾患の診断に不可欠なものとなっており、ヘルスケアにおける画像技術の大規模な浸透が米国市場における造影剤の需要を高めています。がんや糖尿病などの慢性疾患は、急速に公衆衛生の主要な関心事となりつつあり、米国全体の主要な死因の一つとなっているため、早期診断ツールと効果的な治療オプションが必要とされています。

したがって、複雑な併存疾患や長期にわたる疾患の有病率の増加は、画像検査および造影剤の主要な促進要因の一つであり、市場の成長に寄与しています。COVID-19の流行は、病院を訪れる患者の減少により市場に悪影響を及ぼしました。多くの放射線科では画像診断の症例数が急速に減少しました。しかし、米国の多くの州では経済の再開が始まっています。しかし、造影剤の利用率が流行前のレベルに達するには時間がかかります。また、COVID-19ワクチンの発売や規制緩和により、原材料の輸出入が再開されています。このため、予測期間中の市場成長を押し上げることが期待されます。

米国の造影剤市場レポート・ハイライト

• MRIなどの画像検査はほとんどの疾患の診断に欠かせないものとなっており、ヘルスケアにおける画像技術の大規模な普及が米国市場における造影剤の需要を高めています。
• ヨード化造影剤は、他の薬剤に比べて優れた放射線透過性と低毒性であることから、ヨード化造影剤が市場を独占し、2022年には60％以上の最大シェアを占めました。
• X線/CTセグメントが市場を独占し、2022年には約65%の最大シェアを占めました。X線/CTモダリティが広く受け入れられ、コスト効率が高いことが、このモダリティ用の造影剤の採用を後押ししています。
• 画像診断に対する需要の高まりにより、造影剤メーカーは新製品を市場に投入し、新たな適応症の承認を得るために大規模な研究開発活動を行っています。
• 例えば、2021年、Bracco社は超音波造影剤であるLumasonの20バイアルパックの米国FDA承認を取得しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の造影剤市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の造影剤市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の造影剤：タイプの推定・動向分析

• 米国の造影剤市場、タイプ別の重要なポイント
• 米国の造影剤市場：動向と市場シェア分析、2022年および2030年
• マイクロバブル造影剤
• ガドリニウムベースの造影剤
• ヨード造影剤
• バリウムベースの造影剤

第5章 米国の造影剤：モダリティの推定・動向分析

• 米国の造影剤市場、モダリティ別の重要なポイント
• 米国の造影剤市場：動向と市場シェア分析、2022年および2030年
• 超音波
• 磁気共鳴画像法（MRI）
• X線/コンピュータ断層撮影（CTスキャン）

第6章 米国の造影剤：用途の推定・動向分析

• 米国の造影剤市場、用途別の重要なポイント
• 米国の造影剤市場：動向と市場シェア分析、2022年および2030年
• 心臓血管
• 神経学的障害
• 胃腸疾患
• がん
• 腎臓疾患
• 筋骨格系疾患
• その他

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
  • Bayer AG
  • GE Healthcare
  • Guerbet
  • Lantheus Medical Imaging, Inc
  • Bracco Diagnostic Inc
  • Trivitron Healthcare
  • Nano Therapeutics Pvt Ltd.
  • IMAX Diagnostic Imaging
  • CMC Contrast AB (ASCELIA PHARMA AB)

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. U.S. contrast media market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. U.S. contrast media market, by modality, 2018 - 2030 (USD Million)
• Table 4 U.S. U.S. contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. contrast media: Market outlook
• Fig. 9 U.S. contrast media: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 U.S. contrast media market driver impact
• Fig. 15 U.S. contrast media market restraint impact
• Fig. 16 U.S. contrast media market strategic initiatives analysis
• Fig. 17 U.S. contrast media market: Type movement analysis
• Fig. 18 U.S. contrast media market: Type outlook and key takeaways
• Fig. 19 Microbubble Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Gadolinium-based Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Iodinated Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Barium-based Contrast media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 U.S. contrast media market: Modality movement analysis
• Fig. 25 U.S. contrast media market: Modality outlook and key takeaways
• Fig. 26 Ultrasound market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Magnetic resonance imaging (MRI) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 X-ray/computed tomography (CT scan) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 U.S. contrast media market: Application movement analysis
• Fig. 30 U.S. contrast media market: Application outlook and key takeaways
• Fig. 31 Cardiovascular conditions market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Gastrointestinal disorders management market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Nephrological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)

U.S. Contrast Media Market Growth & Trends:

The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth. Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market. Chronic diseases, such as cancer and diabetes, are rapidly becoming a major public health concern and are among the leading causes of death across the U.S., resulting in the need for early diagnostic tools and effective treatment options.

Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth. The COVID-19 outbreak had a negative impact on the market due to decreased patient visits to hospitals. Many radiology departments experienced a rapid decline in imaging case volume. However, many states in the U.S. have begun to reopen their economies; however, it will take time for the utilization rate of contrast media to reach pre-pandemic levels. In addition, with the launch of COVID-19 vaccines and ease in restrictions, the import and export of raw materials have resumed. This, in turn, therefore, is expected to boost the market growth over the forecast period.

U.S. Contrast Media Market Report Highlights:

• Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market
• The iodinated contrast media dominated the market and held the largest market share of over 60% in 2022 on account of excellent radio-opacity and low toxicity of iodinated contrast media than other agents
• The X-ray/CT segment dominated the market and held the largest market share of around 65% in 2022. Wide acceptance and cost-efficiency of X-ray/CT modality boost the adoption of contrast agents for this modality
• The rising demand for imaging procedures has resulted in extensive R&D activities by contrast media manufacturers to launch novel products in the market and to get approved for new indications
• For instance, in 2021, Bracco got the U.S. FDA approval for 20-vial pack configuration of Lumason, which is an ultrasound contrast media agent

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Modality
  • 1.1.3. Application
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Modality outlook
  • 2.2.3. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Contrast Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. U.S. Contrast Media Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. U.S. Contrast Media: Type Estimates & Trend Analysis

• 4.1. U.S. Contrast Media Market, By Type Key Takeaways
• 4.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Microbubble Contrast Media
  • 4.3.1. Microbubble contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Gadolinium-based Contrast Media
  • 4.4.1. Gadolinium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Iodinated Contrast Media
  • 4.5.1. Iodinated contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Barium-based Contrast Media
  • 4.6.1. Barium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Contrast Media: Modality Estimates & Trend Analysis

• 5.1. U.S. Contrast Media Market, By Modality Key Takeaways
• 5.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Ultrasound
  • 5.3.1. Ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Magnetic Resonance Imaging (MRI)
  • 5.4.1. Magnetic resonance (MRI) imaging market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. X-RAY/Computed Tomography (CT Scan)
  • 5.5.1. X-RAY/computed tomography (CT Scan) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Contrast Media: Application Estimates & Trend Analysis

• 6.1. U.S. Contrast Media Market, By Application Key Takeaways
• 6.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Cardiovascular
  • 6.3.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Neurological Disorders
  • 6.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Gastrointestinal Disorders
  • 6.5.1. Gastrointestinal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Cancer
  • 6.6.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Nephrological Disorders
  • 6.7.1. Nephrological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Musculoskeletal Disorders
  • 6.8.1. Musculoskeletal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Bayer AG
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. GE Healthcare
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Guerbet
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Lantheus Medical Imaging, Inc
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Bracco Diagnostic Inc
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Trivitron Healthcare
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Nano Therapeutics Pvt Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. IMAX Diagnostic Imaging
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. CMC Contrast AB (ASCELIA PHARMA AB)
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives